Morgan Stanley
MS
$177.64
-0.29%
Morgan Stanley is a global financial services firm operating primarily in the Capital Markets industry, with core businesses spanning investment banking, institutional securities trading, wealth management, and asset management. The company is a dominant player and market leader, particularly distinguished by its massive wealth and asset management franchises which now generate the lion's share of its income, boasting $9.3 trillion in client assets. The current investor narrative centers on the firm's strategic evolution beyond its traditional investment banking roots, with attention focused on the stability and growth of its fee-based wealth management business, its performance in a potentially volatile capital markets environment, and its ability to navigate interest rate cycles and regulatory landscapes as a systemically important financial institution.…
MS
Morgan Stanley
$177.64
Related headlines
Investment Opinion: Should I buy MS Today?
Rating & Thesis: Morgan Stanley is a Buy for investors seeking a high-quality financial with a growth-oriented profile, anchored by its dominant wealth management franchise and trading at a reasonable valuation with clear upside. This view is supported by a bullish-leaning analyst consensus implying an 18.8% upside to an average target near $211.
Supporting Evidence: The buy thesis is grounded in four specific data points: 1) A forward P/E of 14.32x is justified by superior returns (15.10% ROE) and is near the middle of its own historical range, not egregiously expensive. 2) Revenue growth remains solid at 11.08% YoY, demonstrating business momentum. 3) Profitability is exceptional, with gross margins consistently above 57% and net margins above 15%. 4) The stock offers a 2.36% dividend yield with a sustainable 39% payout ratio, providing income while awaiting capital appreciation.
Risks & Conditions: The two biggest risks are a deeper-than-expected slowdown in capital markets activity, pressuring the Institutional Securities segment, and valuation multiple compression if the Fed maintains restrictive rates. This Buy rating would downgrade to Hold if quarterly revenue growth decelerates below 5% YoY or if the forward P/E expands above 18x without corresponding earnings growth. It would downgrade to Sell if net income declines sequentially for two consecutive quarters. Based on its growth profile, profitability, and peer comparison, the stock is fairly valued to slightly undervalued relative to its long-term opportunity.
Sign up to view all
MS 12-Month Price Forecast
The outlook for Morgan Stanley is positive, with the base case (55% probability) pointing to steady execution and price appreciation toward analyst targets. The firm's transformed business model provides a buffer against capital markets volatility that has historically plagued the stock. The primary near-term catalyst is the performance of the Institutional Securities segment in the next two earnings reports. The stance would be downgraded to neutral if QoQ revenue declines resume or if the forward P/E multiple falls below 13x without a corresponding improvement in the earnings outlook. Conversely, evidence of accelerating organic growth in wealth management could increase confidence and upgrade the stance to bullish with high confidence.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $230.93 and implied upside of +30.0% versus the current price.
Average Target
$230.93
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$142 - $231
Analyst target range
Analyst coverage for Morgan Stanley is substantial, with 7 analysts providing estimates, reflecting its status as a large-cap, institutionally-followed stock. The consensus sentiment leans bullish, as evidenced by recent institutional ratings which include actions like 'Overweight' from Barclays and 'Outperform' from Keefe, Bruyette & Woods, though firms like JP Morgan maintain a 'Neutral' stance. The average target price is implied through estimated EPS; the average EPS estimate is $14.76, which, when applied to the forward PE of 14.32x, suggests a consensus price target near $211, implying approximately 18.8% upside from the current price of $177.64. The target range, derived from EPS estimates, shows a low of $14.16 and a high of $15.54, translating to a price range of roughly $203 to $223 using the forward multiple. The high target likely assumes successful execution in wealth management, a rebound in investment banking, and stable net interest income, while the low target may factor in a weaker capital markets environment and margin compression. The recent pattern of analyst actions shows a series of reiterations rather than major upgrades or downgrades, indicating a period of watchful evaluation. The moderate spread between high and low targets suggests a reasonable level of consensus among analysts on the company's near-term prospects.
Bulls vs Bears: MS Investment Factors
The investment debate for Morgan Stanley centers on the stability of its premium valuation, justified by its high-margin wealth management transformation, against its inherent cyclicality and financial leverage. Currently, the bull case has stronger evidence, supported by superior profitability (15.10% ROE), a clear strategic moat in wealth management, and an 18.8% implied upside to analyst targets. The single most important tension is whether the fee-based wealth management business can continue to deliver stable, high-margin growth sufficient to offset the inevitable volatility and potential earnings pressure from its traditional capital markets operations. The resolution of this tension—specifically, the performance of the Institutional Securities segment in the coming quarters—will be the primary driver of the stock's direction.
Bullish
- Strong Wealth Management Growth: Morgan Stanley's strategic pivot to wealth and asset management is paying off, with the segment generating $8.43B in a recent quarter and underpinning a robust 58.02% gross margin. The firm's $9.3T in client assets provides a massive, stable fee-based revenue stream that is less cyclical than investment banking.
- Superior Profitability & ROE: The company exhibits high-quality earnings with a net margin of 15.24% and a Return on Equity of 15.10%, indicating efficient use of shareholder capital. This profitability, driven by scalable operations, justifies a valuation premium over traditional banks.
- Attractive Valuation with Upside: At a forward P/E of 14.32x, the stock trades at a moderate premium justified by its business mix. The implied analyst target of ~$211 suggests 18.8% upside from the current price of $177.64, supported by a consensus EPS estimate of $14.76.
- Resilient Long-Term Trend: Despite recent volatility, the stock maintains a strong 1-year price change of +66.67%, significantly outperforming the SPY (+29.52%). The current price is a meaningful pullback from its 52-week high, offering a potential entry point in a sustained uptrend.
Bearish
- Revenue Growth Deceleration: Q4 2025 revenue of $28.86B declined sequentially from Q3's $30.05B, signaling potential cyclical pressure in capital markets. While YoY growth was 11.08%, the peak suggests normalization, which could pressure the premium valuation if the trend continues.
- Elevated Financial Leverage: The company carries a high debt-to-equity ratio of 4.26, which is typical for large financial institutions but amplifies risk during economic downturns or periods of rising interest rates. This leverage necessitates consistent profitability to service obligations.
- High Beta & Market Volatility: With a beta of 1.182, Morgan Stanley's stock is approximately 18% more volatile than the broader market. This makes it susceptible to sharp drawdowns during risk-off periods, as evidenced by its recent 3-month loss of -4.66% versus SPY's -2.1%.
- Negative Free Cash Flow: The trailing twelve-month free cash flow is deeply negative at -$17.89B, which, while common for broker-dealers due to accounting classifications, limits financial flexibility for shareholder returns outside of earnings and could concern investors focused on cash generation.
MS Technical Analysis
The stock is in a sustained long-term uptrend but has recently experienced significant volatility and a sharp pullback from its highs. With a 1-year price change of +66.67%, the trend is strongly positive; however, the current price of $177.64 sits at approximately 63% of its 52-week range ($102.89 to $192.68), indicating it has retreated meaningfully from its peak and is now in the lower-middle portion of its annual band. This positioning suggests the momentum-driven rally has cooled, presenting a potential consolidation or value entry point after the correction, though it remains well above its lows. Recent momentum shows a stark divergence, with a strong 1-month gain of +10.41% contrasting with a 3-month loss of -4.66%. This indicates a significant rebound attempt in the very short term following a deeper sell-off, potentially signaling a trend reversal or a relief rally within a broader corrective phase. The stock's beta of 1.182 confirms it is approximately 18% more volatile than the broader market (SPY), which is relevant for risk-adjusted positioning. Key technical levels are clearly defined, with immediate resistance near the 52-week high of $192.68 and support at the 52-week low of $102.89. A breakout above the recent recovery highs near $180-$190 would signal a resumption of the primary uptrend, while a breakdown below the March 2026 lows near $154 would indicate a deeper correction is underway, potentially testing stronger support levels.
Beta
1.18
1.18x market volatility
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$105-$193
Price range past year
Annual Return
+66.7%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | +10.4% | +2.6% |
| 3m | -4.7% | -2.3% |
| 6m | +17.0% | +2.6% |
| 1y | +66.7% | +27.3% |
| ytd | -2.3% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Revenue growth has been solid but shows signs of sequential deceleration. The most recent quarterly revenue (Q4 2025) was $28.86 billion, representing a healthy year-over-year growth rate of 11.08%. However, examining the multi-quarter trend reveals revenue peaked in Q3 2025 at $30.05 billion before dipping in Q4, suggesting potential cyclical pressure or normalization in capital markets activity. Segment data from a recent quarter shows the Wealth Management segment contributed $8.43 billion, Institutional Securities $7.93 billion, and Investment Management $1.72 billion, indicating a balanced revenue mix. The company is highly profitable with robust margins. Net income for Q4 2025 was $4.40 billion, translating to a net margin of 15.24%. The gross margin for the quarter was a strong 58.02%. Profitability has been consistent, with net income figures over the past four quarters ranging from $3.54 billion to $4.62 billion, and gross margins have remained stable in the high-50% range, reflecting the firm's pricing power and scalable business model, particularly in wealth management. The balance sheet is leveraged but supported by strong profitability metrics. The debt-to-equity ratio is elevated at 4.26, which is typical for a large financial institution. Return on Equity (ROE) is a robust 15.10%, indicating efficient use of shareholder capital. A point of concern is the trailing twelve-month free cash flow, which is deeply negative at -$17.89 billion; this is common for banks and broker-dealers due to the classification of certain trading and lending activities within operating cash flow, and the firm's financial health is better assessed through its capital ratios and earnings power rather than traditional FCF for industrial companies.
Quarterly Revenue
$28.9B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$-17.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
Given the company's substantial positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 16.54x, while the forward PE is lower at 14.32x. The gap between trailing and forward multiples implies the market anticipates earnings growth, with analysts expecting future profitability to improve relative to the last twelve months. Compared to industry averages, Morgan Stanley's valuation appears to be at a moderate premium. Its trailing PE of 16.54x and forward PE of 14.32x are above the typical range for large-cap financials, which often trade in the low-teens. This premium is likely justified by the firm's superior mix shift towards higher-multiple, stable fee-based wealth and asset management revenues, as opposed to being purely a cyclical investment bank. Historically, the stock's current trailing PE of 16.54x is near the middle of its own historical range observed in the provided data, which has fluctuated from approximately 8.5x to over 24x in recent years. This suggests the stock is not at extreme valuation levels relative to its own history; it is neither priced for peak optimism (as seen in 2021-2022 with PEs above 20x) nor deep pessimism, potentially offering a balanced entry point if fundamentals remain intact.
PE
16.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Morgan Stanley's primary financial risk stems from its elevated leverage, with a debt-to-equity ratio of 4.26, which magnifies losses in adverse scenarios. While profitability is robust with a 15.24% net margin, the company is not immune to earnings volatility, as seen in the sequential revenue decline from Q3 to Q4 2025. Furthermore, the deeply negative TTM free cash flow of -$17.89B, though a sector norm, indicates that shareholder returns are entirely dependent on net income, leaving less cushion for dividends and buybacks during downturns.
Market & Competitive Risks: The stock trades at a forward P/E of 14.32x, a premium to many large-cap financial peers, creating valuation compression risk if growth decelerates or capital markets weaken. Its beta of 1.182 confirms high sensitivity to broader market swings, making it vulnerable to sector rotations away from financials or risk-off sentiment driven by macro or geopolitical events, as highlighted in recent news. Competitive disruption from fintech and changing interest rate dynamics also pose persistent threats to net interest income and fee structures.
Worst-Case Scenario: A severe recession coupled with a capital markets freeze could trigger a chain where investment banking revenue collapses, wealth management fees decline due to lower asset values, and credit losses rise. This could compress the forward P/E toward 10x and drive earnings below estimates. The realistic downside could see the stock retest its 52-week low of $102.89, representing a potential loss of approximately -42% from the current price of $177.64. A more probable adverse scenario, aligning with the analyst low target implied range near $203, would still imply a -10% to -15% decline.
FAQ
The key risks are: 1) Cyclical & Financial Risk: High debt-to-equity (4.26) and reliance on capital markets revenue, which declined sequentially last quarter. 2) Market Risk: Stock volatility (beta 1.182) makes it prone to sharp drawdowns during market corrections. 3) Valuation Risk: Trading at a premium forward P/E (14.32x) creates compression risk if growth disappoints. 4) Operational Risk: Negative TTM free cash flow of -$17.89B, while sector-typical, limits financial flexibility. The most severe near-term risk is a prolonged slump in investment banking activity pressuring earnings and the premium multiple.
The 12-month forecast centers on a base case (55% probability) with a target range of $203-$223, driven by meeting consensus EPS of ~$14.76 and a stable forward P/E multiple. The bull case (30% probability) targets $223-$235 on multiple expansion and stronger capital markets, while the bear case (15% probability) sees a drop to $155-$180 on earnings misses and multiple compression. The most likely outcome is the base case, which assumes the wealth management segment offsets mild cyclical pressure elsewhere, leading to modest price appreciation. The key assumption is the stability of the firm's high-margin, fee-based revenue streams.
MS appears fairly valued to slightly undervalued based on its growth profile. Its forward P/E of 14.32x is at a moderate premium to many large-cap bank peers, but this is justified by its superior return profile (15.10% ROE) and higher-margin business mix. Historically, its trailing P/E of 16.54x is near the middle of its own range, suggesting it is not at an extreme. The valuation implies the market expects steady mid-to-high single-digit earnings growth, which seems achievable given the firm's strategic positioning. Compared to its own potential, the stock is not overvalued.
MS presents a compelling risk/reward profile for investors comfortable with financial sector volatility. The stock offers an estimated 18.8% upside to the analyst consensus target near $211, supported by strong profitability (15.10% ROE) and a dominant wealth management business. The key downside risk is a cyclical downturn in capital markets, which could compress its premium valuation. It is a good buy for long-term investors seeking a high-quality financial with growth characteristics, but may be less suitable for risk-averse or short-term traders due to its 1.182 beta and recent price volatility.
MS is better suited for a long-term investment horizon of 3-5 years. Its 1.182 beta and exposure to economic cycles make it volatile for short-term trading. The firm's strategic value is derived from the multi-year compounding of its $9.3T wealth management asset base, a story that unfolds over quarters and years, not weeks. While it pays a 2.36% dividend, it is not primarily an income stock. Given the need to ride out capital markets cycles to realize the full benefit of its business mix, a minimum holding period of 18-24 months is recommended to allow the investment thesis to play out.